In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Massachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it matters: Diabetes patients are often paying hundreds of dollars a month or ...
Campbell’s lawsuit highlights the impact PBMs have on one drug. In Massachusetts, about 500,000 residents are living with diabetes, nearly all of whom rely on the daily use of insulin to survive.